Design of the POSSIBLE US™ Study: postmenopausal women’s compliance and persistence with osteoporosis medications

[1]  T. Weiss,et al.  Osteoporosis practice patterns in 2006 among primary care physicians participating in the NORA study , 2007, Osteoporosis International.

[2]  J. Cramer,et al.  A systematic review of persistence and compliance with bisphosphonates for osteoporosis , 2007, Osteoporosis International.

[3]  S. Silverman,et al.  Effectiveness of bisphosphonates on nonvertebral and hip fractures in the first year of therapy: The risedronate and alendronate (REAL) cohort study , 2006, Osteoporosis International.

[4]  S. Silverman,et al.  Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. , 2006, Mayo Clinic proceedings.

[5]  G. Oster,et al.  Compliance with drug therapy for postmenopausal osteoporosis , 2006, Osteoporosis International.

[6]  D. Gold.  Medication Adherence , 2006, Journal of managed care pharmacy : JMCP.

[7]  Krista F Huybrechts,et al.  Assessment of compliance with osteoporosis treatment and its consequences in a managed care population. , 2006, Bone.

[8]  K. Kahler,et al.  Adherence and Persistence Associated with the Pharmacologic Treatment of Osteoporosis in a Managed Care Setting , 2006, Southern medical journal.

[9]  A. Westfall,et al.  Channeling and adherence with alendronate and risedronate among chronic glucocorticoid users , 2006, Osteoporosis International.

[10]  B. Ettinger,et al.  Persistence with weekly alendronate therapy among postmenopausal women , 2006, Osteoporosis International.

[11]  S. Giannini,et al.  Determinants of adherence to osteoporosis treatment in clinical practice , 2006, Osteoporosis International.

[12]  R. Recker,et al.  Effect of dosing frequency on bisphosphonate medication adherence in a large longitudinal cohort of women. , 2005, Mayo Clinic proceedings.

[13]  A. Scillitani,et al.  Osteoporosis intervention in ambulatory patients with previous hip fracture: a multicentric, nationwide Italian survey , 2005, Osteoporosis International.

[14]  R. Stafford,et al.  National trends in osteoporosis visits and osteoporosis treatment, 1988-2003. , 2004, Archives of internal medicine.

[15]  Krista F. Huybrechts,et al.  The impact of compliance with osteoporosis therapy on fracture rates in actual practice , 2004, Osteoporosis International.

[16]  M. Atkinson,et al.  Health and Quality of Life Outcomes , 2004 .

[17]  G. Herrero-Beaumont,et al.  Compliance and satisfaction with raloxifene versus alendronate for the treatment of postmenopausal osteoporosis in clinical practice: An open-label, prospective, nonrandomized, observational study. , 2004, Clinical therapeutics.

[18]  J. Mccombs,et al.  Compliance with drug therapies for the treatment and prevention of osteoporosis. , 2003, Maturitas.

[19]  S. Silverman.  The Osteoporosis Assessment Questionnaire (OPAQ): A reliable and valid disease-targeted measure of health-related quality of life (HRQOL) in osteoporosis , 2000, Quality of Life Research.

[20]  S. Ish-shalom,et al.  Compliance of osteoporotic patients with different treatment regimens. , 2003, The Israel Medical Association journal : IMAJ.

[21]  S. Emani,et al.  Compliance with pharmacologic therapy for osteoporosis , 2003, Osteoporosis International.

[22]  K. McCoy,et al.  Tolerability and compliance with risedronate in clinical practice , 2003, Osteoporosis International.

[23]  E. Barrett-Connor,et al.  Design of NORA, the National Osteoporosis Risk Assessment Program: a longitudinal US registry of postmenopausal women. , 1998, Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA.

[24]  J. Adachi.  Current treatment options for osteoporosis. , 1996, The Journal of rheumatology. Supplement.

[25]  R. Brooks.  EuroQol: the current state of play. , 1996, Health policy.